1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kobo Biotech Ltd

Kobo Biotech Ltd

BBSE:KOBO
4.11
INR
-0.08
(-1.91%)
-2.12EPS
90.54MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
179.4
25.28
12.92
13.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
6.22
-13.99
-13.45
-6.94
-8.07
-10.04
-10.27
-8.82
-8.07
-6.39
-2.33
-2.07
-2.2
-2.12
Free Cash Flow per Basic Share
12.83
2.81
8.59
- -
13.55
13.21
8.79
6.08
1.05
39.35
0.37
1.07
1.75
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
39.06
19.81
6.08
2.71
-7.8
-17.84
-28.11
-36.92
-45
-51.39
-53.72
-55.79
-57.98
- -
Tangible Book Value per Share
39.06
19.81
6.08
2.71
-7.8
-17.84
-28.11
-36.92
-45
-51.39
-53.72
-55.79
-57.98
- -
Basic Weighted Avg Shares
23
23
22
24
24
24
24
24
24
24
24
24
24
24
Sales/Revenue/Turnover
4,037
569
291
325
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
8.16
-29.13
-60.94
-10.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
100
96
78
73
68
64
61
59
56
46
41
41
41
41
Net Income, GAAP
140
-315
-303
-165
-192
-239
-245
-210
-192
-152
-56
-49
-52
-50
Effective Tax Rate (%)
8.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3.47
-55.35
-104.13
-50.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
445
56
-218
-197
-505
-850
-1,098
-1,249
-1,399
-1,258
-1,281
-1,299
-1,311
- -
LT Debt
331
760
711
710
584
414
349
349
335
335
327
317
317
- -
Total Equity
879
446
137
64
-186
-425
-670
-880
-1,072
-1,224
-1,280
-1,329
-1,381
- -
Return on Invested Capital (%)
16.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
7.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
17.3
-47.54
-103.9
-163.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'24
Mar'24
Jun'25
ST Debt
- -
1,080
- -
LT Borrowings
- -
317
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
74
91
91

Working Capital

INR

•

in mil. unless spec.
Dec'24
Mar'24
Jun'25
Total Current Assets
- -
379
- -
Cash, Cash Equivalents & STI
- -
2
- -
Accounts Receivable, Net
- -
120
- -
Inventories
- -
180
- -
Total Current Liabilities
- -
1,678
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,080
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.61%
9.68%
3.93%
Free Cash Flow
- -
742.12%
63.11%
Net Income, GAAP
-11.42%
-19.59%
6.11%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.62
-0.46
-0.5
-0.75
-2.33
2024
-0.51
-0.51
-0.52
-0.53
-2.07
2025
-0.56
- -
- -
- -
-2.2

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Neelam Kumar Murdia
Full Time Employees
484
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hyde Park Hyderabad TS India 400072
IPO Date
Jan 8, 1996
Website
kobobiotech.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kobo Biotech Limited manufactures active pharmaceutical ingredients using fermentation technology at its facility in Solapur, Maharashtra, spread over 21 acres; the company produces pharmaceutical intermediates, including ephedrine and pseudo-ephedrine with an installed capacity of 150 metric tons per annum, as well as agrochemical and pigment intermediates. Incorporated in 1993 and headquartered in Mumbai, India, with a registered office in Hyderabad, Telangana, Kobo Biotech operates primarily in the pharmaceuticals and biotechnology segments, serving domestic and international markets with a focus on bulk drugs and APIs. Formerly known as Avon Lifesciences Limited, the company changed its name in October 2020; it currently faces financial challenges, including ongoing proceedings under the Corporate Insolvency Resolution Process as evidenced by regular Committee of Creditors meetings through 2025 and reported losses, such as a net loss of INR 1.33 crore in the first quarter of fiscal 2025, with operational activities at the Solapur facility at a standstill.